Mirum : FDA Approves Atebrioz For Rare Bone Disorder FOP In Patients Aged 12 And Older

The FDA approved Atebrioz (zilurgisertib) tablets from Mirum Pharmaceuticals and Incyte to reduce the volume of new heterotopic ossification in adults and patients aged 12 and older. The approval creates a new commercial opportunity in a rare-disease indication and is a materially positive regulatory catalyst for both companies.